Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4

University of Colorado Denver (CU Denver)

Status and phase: Withdrawn; Phase 2

Conditions: Heroin Dependence; Opioid-Related Disorders

Treatments: Drug: Opioid-Related Disorders

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00000329

R01-11160-4

NIDA-11160-4

R01DA011160 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in buprenorphine-naloxone maintained volunteers

Full description

Ongoing study - results not available at this time

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Individuals must be at least 18 yrs of age, currently opioid dependent and meet FDA criteria for narcotic maintenance treatment. Co-morbid substance abuse or dependence disorders may also be present. Individuals must be healthy despite drug dependency and have a history of IV opioid use.

Exclusion criteria

Individuals with evidence of anti active Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.